Autolus Therapeutics taps investors for $100m

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
ABBs-Block Trades

Autolus Therapeutics taps investors for $100m

Aidan Gregory
February 09, 2021 12:00 pm
biotech_microscope_drug_production_adobe_575x375_oct13
Medical science laboratory. Concept of virus research | Alphaspirit/alphaspirit - stock.adobe.com

Autolus Therapeutics, the UK biopharmaceutical company focused on T cell therapies for cancer, is raising additional capital on the Nasdaq.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP MorganHealth and BiotechEquityABBs-Block TradesUKEuropeEMEASRI
AG
Aidan Gregory
Gift this article